NCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
Clinical Trials
14 trialsNCT04270864 2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT02944864 2024-09-23
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT05128539 2024-03-26
A Study Explore JS001+JS002 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05154630 2024-01-18
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT03444753 2022-05-23
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
Phase 1 Terminated
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT00895024 2020-10-29
Caregiver Assessments of the Quality of Home Hospice Care
M.D. Anderson Cancer Center
Terminated
NCT02992977 2020-06-02
Safety and Tolerability Study of AutoSynVaxâ„¢ Vaccine in Subjects With Advanced Cancer
Agenus Inc.
Phase 1 Terminated
NCT01394003 2019-01-18
A Study of LY2584702 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT01688791 2015-02-10
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Endocyte
Phase 1 Terminated
NCT02136342 2014-10-21
Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
ChineseAMS
Phase 1 Terminated
NCT00606879 2008-07-24
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00607399 2008-07-24
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
Phase 1 Terminated